SEMAGLUTIDE — all Canadian products
49 DINs
48 marketed/approved
1 in shortage
Every Health Canada Drug Identification Number whose active ingredient is SEMAGLUTIDE, with holder, form, strength and current status, compared weekly against the Drug Product Database.
| DIN | Product | Company | Form | Route | Strength | Status | Shortage |
|---|---|---|---|---|---|---|---|
| 02568020 | APO-SEMAGLUTIDE INJECTION | APOTEX INC | Solution | Subcutaneous | SEMAGLUTIDE 0.68 MG | Marketed | |
| 02568012 | APO-SEMAGLUTIDE INJECTION | APOTEX INC | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Marketed | |
| 02569949 | ASPEN-SEMAGLUTIDE | ASPEN PHARMACARE CANADA INC. | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02569930 | ASPEN-SEMAGLUTIDE | ASPEN PHARMACARE CANADA INC. | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02562618 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02471469 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Marketed | |
| 02523930 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2.68 MG | Approved | |
| 02562626 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2.68 MG | Approved | |
| 02540258 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 0.68 MG | Marketed | |
| 02564076 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02564041 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 0.68 MG | Approved | |
| 02568233 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02568241 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2.68 MG | Approved | |
| 02564068 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02564084 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2.68 MG | Approved | |
| 02564211 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 9.6 MG | Approved | |
| 02564106 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 0.25 MG | Approved | |
| 02564114 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 0.5 MG | Approved | |
| 02564122 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1 MG | Approved | |
| 02564130 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.7 MG | Approved | |
| 02564149 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2.4 MG | Approved | |
| 02564157 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1 MG | Approved | |
| 02564165 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2 MG | Approved | |
| 02564173 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2 MG | Approved | |
| 02564181 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 4 MG | Approved | |
| 02564203 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 6.8 MG | Approved | |
| 02497603 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | Oral | SEMAGLUTIDE 7 MG | Marketed | |
| 02551012 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | Oral | SEMAGLUTIDE 1.5 MG | Marketed | |
| 02551020 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | Oral | SEMAGLUTIDE 4 MG | Marketed | |
| 02497581 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | Oral | SEMAGLUTIDE 3 MG | Marketed | |
| 02551039 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | Oral | SEMAGLUTIDE 9 MG | Marketed | |
| 02497611 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | Oral | SEMAGLUTIDE 14 MG | Marketed | |
| 02567814 | SEMAGLUTIDE INJECTION | DR REDDY'S LABORATORIES LTD | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Marketed | |
| 02567806 | SEMAGLUTIDE INJECTION | DR REDDY'S LABORATORIES LTD | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Marketed | Yes |
| 02570912 | SEMAGLUTIDE INJECTION | ASPEN PHARMACARE CANADA INC. | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02570920 | SEMAGLUTIDE INJECTION | ASPEN PHARMACARE CANADA INC. | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Approved | |
| 02569582 | SEVMIA | APOTEX INC | Solution | Subcutaneous | SEMAGLUTIDE 4 MG | Approved | |
| 02522594 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.7 MG | Approved | |
| 02522551 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 0.25 MG | Approved | |
| 02528525 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 4 MG | Marketed | |
| 02522586 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1 MG | Approved | |
| 02522578 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 0.5 MG | Approved | |
| 02552698 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2 MG | Approved | |
| 02528541 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 9.6 MG | Marketed | |
| 02528533 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 6.8 MG | Marketed | |
| 02528517 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2 MG | Marketed | |
| 02528509 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1 MG | Marketed | |
| 02522608 | WEGOVY | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 2.4 MG | Approved | |
| 02471477 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | Subcutaneous | SEMAGLUTIDE 1.34 MG | Dormant |
Browse other molecules: